Saturday, 19 November 2016

Euro Biosimilars 2017

About Conference

The Organizing Committee  is delighted to invite you to attend the 7th European Biosimilars Congress  one of its remarkable Pharmaceutical conferences, to be held during May 15-17, 2017 in Munich, Germany. European Biosimilars Congress 2017 brings together scientists, researchers and CROs from around the world. With the approval of second biosimilar by the USFDA-Inflectra the biosimilars market is owned to experience a exponential growth over the coming few years. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.
At Euro Biosimilars 2017 meet your target audiences from around the world focused on learning about biologics and biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and biosimilars community.
Why to attend???
Conduct demonstrations, distribute information, meet with current and potential Scientists to update yourself with latest technological advancememts and new research, and receive name recognition at this 3-days' event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in the era of follow-on-biologics and biosimilars are hallmarks of this conference.
Target Audience:
  • Directors, CEO’s of Organizations
  • Business Development Managers
  • Chief Scientific Officers
  • R&D Researchers from Biosimilar and Bioslogics Industries
  • Professors, Associate Professors, Assistant Professors
  • PhD Scholars
  • Patent Attorneys
  • Intellectual Property Attorneys
  • Investment Analysts
  • Association, Association presidents and professionals
  • Noble laureates in Health Care and Medicine
  • Bio instruments Professionals
  • Bio-informatics Professionals
  • Software development companies
  • Research Institutes and members
  • Supply Chain companies
  • Manufacturing Companies
  • CRO and DATA management Companies
  • Training Institutes
  • Business Entrepreneurs
Past Attendees Share Based on Professional Sectors:






Market Analysis

As per market researchers, the global biosimilar market is expected to be worth $24 billion in 2019-at compound annual growth rate (CAGR) of some 65% from 2014.Clinical trials at global level would incur an approximate cost of few hundred crores.The estimated cost of developing biosimilars for global markets is $75-250 million, while developing traditional non-biologic generics costs about $2-3 million. With the introduction of Inflectra on April 06, 2016 the Biosimilar Market will grow at even higher rate.
Critical Analysis:
The capital-intensive nature of the biosimilar business and long gestation periods between initial investment
and commercialization require biosimilar players to take a higher level of risk than their counterparts in the smallmolecule generics business, and this can be a significant barrier to entry for many start-ups.
Growth Potential of Biologics and Biosimilars Market in Germany
Potential factors to affect biosimilars market penetration:
Importance & Scope:
The European-based pharmaceutical industry makes a major contribution to the Europe, not just in financial terms but also in terms of high-trait employment. Globally Pharma Market ranges from $870-$900 billion and in Europe $260-$280 billion.
Major Biosimilars Associations in Europe



Past Conference Report

Euro Biosimilars 2016
Conference Series LLC hosted the 5th European Biosimilars Congress at Hotel MeliĆ” Valencia in Valencia, Spain during June 27-29, 2016.The conference was designed around the theme of “The European perspective of Biologics and Biosimilars” and was a great success where eminent keynote speakers from various reputed companies made their resplendent presence and addressed the gathering. Moreover, the networking sessions laid the foundation for some time worthy collaborations between many start-up and big industries. The post conference networking lunch session witnessed a number of B2B meetings that are turning up to be mutually beneficial to both the organizations who had gone in for the business meetings.
Euro Biosimilars 2016 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Biologics and Biosimilars. This congress not only brought forward the latest developments in the field but also provided solutions to the numerous challenges encountered in developing a biosimilar.
Conference Series LLC would like to convey a warm gratitude to all the Honorable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation in Euro Biosimilars 2016.
Laszlo Endrenyi, University of Toronto, Canada
Candida Fratazzi, BBCR Consulting, USA
Kamali Chance, Quintiles Inc., USA
Andreu Soldevila, Lean Biopro, Spain
Ruideger Janwkosky, Cinfa Biotech GmbH, Germany

We on behalf of the conference specially thank the exhibitors for their participation in the congress and  also the media partners for their wonderful marketing of the event. Conference Series LLC also took the privilege of felicitating Euro Biosimilars 2016 Organizing Committee, Keynote Speakers, Chair and Co-Chairs whose support made conference a great success.
With the enormous feedback from the participants and supporters of Euro Biosimilars 2016, we are glad to announce 7th European Biosimilars Congress during May 15-17, 2017 at Munich, Germany and also invite you to participate at our 6th International Conference and Exhibition on Biologics and Biosimilars through October 19-21, 2016 at Houston, TX, USA.


Past Reports  Gallery  



Past Conference Report

Biosimilars 2015
We hosted the 4th International Conference and Exhibition on Biologics and Biosimilars at Double Tree by Hilton Hotel Baltimore, USA during October 26-28, 2015.The conference was designed around the theme of “ The future of Next Generation Biologics and Biosimilars”  and was a great success where eminent keynote speakers from various reputed companies made their resplendent presence and addressed the gathering.
Biosimilars 2015 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Biologics and Biosimilars.
OMICS International would like to convey a warm gratitude to all the Honorable guests, Keynote Speakers, Media Partners, Exhibitors and Covance Laboratories as sponsors of Biosimilars 2015:
Patrick Lucy, Pfenex Inc., USA
Kamali Chance, Quintiles Inc., USA
Christopher Leintz, Pfizer, USA
Mark A Emalfarb,  Dyadic Internatrional, USA
Sarfaraz K NIazi, Therapeutic Proteins International, USA
Angela Furlanetto, Dimock Stratton LLP, Canada

On behalf of the conference, we congratulate the Best Poster awardees for their outstanding performance and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours.

We had taken the privilege of felicitating Biosimilars 2015 Organizing Committee, Keynote Speakers, Chair and Co-Chairs whose support made conference a great success.
With the enormous feedback from the participants and supporters of Biosimilars 2015, OMICS International is glad to announce 5th European Biosimilars Congress during June 27-29, 2016 at Valencia, Spain and 6th International Conference and Exhibition on Biologics and Biosimilars through October 20-22, 2016 at Houston, USA

Past Reports  Gallery   


Special Issues

All accepted abstracts will be published in respective Journals.
Abstracts will be provided with Digital Object Identifier by CrossRef